Up-Regulation of the Cardiac Lipid Metabolism at the Onset of Heart Failure by AbdAlla, Said et al.
190  Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011, 9, 190-206  
   1871-5257/11 $58.00+.00  © 2011 Bentham Science Publishers 
Up-Regulation of the Cardiac Lipid Metabolism at the Onset of Heart   
Failure 
Said AbdAlla
1, Xuebin Fu
1, Sherif S. Elzahwy
2, Kristin Klaetschke
3, Thomas Streichert
3  
and Ursula Quitterer
1,* 
1Molecular Pharmacology Unit, Swiss Federal Institute of Technology and University of Zurich, Zurich, Switzerland; 
2Cardiology Department, Ain Shams University Hospitals, Cairo, Egypt; 
3Department of Clinical Chemistry/Central 
Laboratories, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany 
Abstract: Chronic pressure overload and atherosclerosis are primary etiologic factors for cardiac hypertrophy and failure. 
However, mechanisms underlying the transition from hypertrophy to heart failure are incompletely understood. We   
analyzed the development of heart failure in mice with chronic pressure overload induced by aortic constriction and  
compared the results with aged apolipoprotein E-deficient mice suffering from advanced atherosclerosis. We combined 
cardiac function analysis by echocardiography and invasive hemodynamics with a comprehensive microarray gene   
expression study (GSE25765-8). The microarray data showed that the onset of heart failure induced by pressure overload 
or advanced atherosclerosis was accompanied by a strong up-regulation of key lipid metabolizing enzymes involved in fat 
synthesis, storage and oxidation. Cardiac lipid overload may be involved in the progression of heart failure by enhancing 
cardiomyocyte death. Up-regulation of the cardiac lipid metabolism was related to oxygen and ATP depletion of failing 
hearts because anti-ischemic treatment with ranolazine normalized the cardiac lipid metabolism and improved cardiac 
function. Vice versa, inhibition of cellular respiration and ATP generation by mild thiol-blocking with cystamine triggered 
the cardiac lipid metabolism and caused signs of heart failure. Cardiac tissue specimens of patients with heart failure  
also showed high protein levels of key fat metabolizing enzymes as well as lipid accumulation. Taken together, our  
data strongly indicate that up-regulation of the cardiac lipid metabolism and myocardial lipid overload are underlying the 
development of heart failure. 
Keywords: Aortic constriction, atherosclerosis, heart failure, lipid metabolism, microarray gene expression analysis, pressure 
overload, ranolazine.  
INTRODUCTION 
Cardiovascular disease is still the leading cause of death. 
Current research focuses on pathomechanisms and risk fac-
tors. Hypertension and stable atherosclerosis are major "si-
lent" risk factors for the development cardiac disease and 
cardiac death. Among several pathological events, cardiac 
hypertrophy develops as a major consequence of persistent 
pressure and volume overload. Molecular and cellular 
changes in hypertrophied hearts that initially mediate en-
hanced function are considered key events in the deteriora-
tion of heart function and the development of heart failure. 
Likewise, hypertrophy of the left ventricle is an independent 
predictor of cardiovascular dysfunction, mortality and sud-
den death, and in many pathological conditions, precedes 
congestive heart failure [1].  
Abnormal myocardial metabolism is a key feature ac-
companying hypertrophy-induced pathomechanisms culmi-
nating finally in heart failure [2]. Dysregulation of cardiac 
energy generation may account for the myocardial energy 
depletion, which is a major characteristic of cardiac hyper- 
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trophy and heart failure [3, 4]. The cardiac energy metabo-
lism relying principally (up to 70 %) on free fatty acids 
(FFA) for energy generation is considered one factor under-
lying the development of energy deficiency in heart failure 
because fatty acid oxidation requires about 11 % more oxy-
gen for a given quantity of ATP synthesis than do carbohy-
drates. Moreover, the full impact of exaggerated oxygen 
consumption due to cardiac FFA oxidation may be much 
greater in vivo as a switch from maximal glucose to maximal 
FFA utilization induces an increase in oxygen requirement 
by 50 to 60 % in animal models [5].  
In the course of heart failure, substrate utilization of free 
fatty acids and glucose declines, whereas plasma levels of 
free fatty acids, glucose and insulin are commonly increased 
[2, 6]. In addition to disturbed substrate utilization, the sec-
ond step of cardiac energy generation, i.e. oxidative phos-
phorylation by cardiac mitochondria, is also impaired in 
heart failure [2]. Inefficient oxidative phosphorylation by the 
failing heart could be in part due to the increased expression 
of uncoupling proteins (UCP), which cause mitochondria to 
produce heat rather than ATP [7, 8]. Cardiac UCP expres-
sion may be directly related to the increased plasma levels of 
free fatty acids in heart failure because infusion of free fatty 
acids triggers the expression and activation of UCP under 
experimental conditions [8, 9]. Cardiac Lipid Metabolism in Heart Failure  Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011, Vol. 9, No. 3    191 
In view of the increasing knowledge of the metabolic 
dysfunction in the course of heart failure, the concept arises 
that metabolic intervention could provide an adjuvant ther-
apy for heart failure [6, 10]. However, currently it is not 
quite clear whether a shift from fatty acid towards glucose 
utilization should be considered beneficial or detrimental, 
because inhibition of mitochondrial fatty acid oxidation may 
enhance the accumulation of triglycerides and potentially 
toxic fatty acid intermediates thereby aggravating lipo- 
toxicity [6].  
To further understand the complex events marking the 
transition from cardiac hypertrophy to heart failure we per-
formed whole genome microarray gene expression profiling 
of different experimental models of cardiac failure triggered 
by pressure overload and advanced atherosclerosis. Our 
study provides strong evidence that the onset of heart failure 
is characterized by the up-regulation of the cardiac lipid me-
tabolism and toxic lipid overload. 
MATERIALS AND METHODS 
Chronic Pressure Overload-Induced Cardiac Hypertro-
phy and Heart Failure 
Abdominal aortic constriction (AAC) was used to trigger 
pressure overload-induced cardiac hypertrophy and heart 
failure. All mice were fed a standard rodent chow containing 
4.5 % fat. Aortic constriction of the abdominal aorta was 
performed in anesthetized 4 month-old male C57BL/6J (B6) 
mice or apolipoprotein E-deficient (ApoE
-/-) mice, respec-
tively, as described [11]. Briefly, the abdominal aorta was 
constricted between the celiac and superior mesenteric artery 
by tying a 7-0 silk suture ligature against a blunt 28-gauge 
needle. Age-matched control mice underwent identical sur-
gical procedure except for ligation of the aorta (sham-
operated mice). Cardiac parameters of mice were monitored 
regularly by echocardiography at 1, 2, 4 and 6 months after 
aortic constriction. A group of B6 mice with signs of heart 
failure (ejection fraction <35 %) were treated with ranolazine 
(200 mg/kg/d) initiated 4 months after aortic constriction. 
At the end of the observation period, we determined car-
diac function of all groups of mice: (i) B6 mice with 1 month 
of AAC, (ii) treated/untreated B6 mice with 6 months of 
AAC, and (iii) ApoE
-/- mice with 2 months of AAC. Age-
matched, sham-operated ApoE
-/- and B6 mice served as con-
trols. Mice were anesthetized, cardiac function parameters 
were determined by echocardiography and invasive hemo-
dynamics followed by intracardial perfusion with sterile 
PBS. Hearts were isolated, and heart weight was determined. 
Hearts were immediately frozen in liquid nitrogen, or proc-
essed for further use. 
Experimental Model of Advanced Atherosclerosis-
Induced Heart Failure 
As a model of atherosclerosis-induced heart failure we 
used 18 month-old ApoE
-/- mice, which were on a C57BL/6J 
background, and C57BL/6J (B6) control mice. Until 18 
months of age, ApoE
-/- mice were kept on a 12 h light/12 h 
dark regime, had free access to food and water, and were fed 
a rodent chow containing 7 % fat and 0.15 % cholesterol 
(AIN-93-based diet). To assess the effect of anti-ischemic 
treatment, a group of 16 month-old ApoE
-/- mice with signs 
of heart failure (ejection fraction <35 %) were treated with 
ranolazine (200 mg/kg/d) for 2 months. At an age of 18 
months, all mice were anesthetized, and cardiac function 
parameters were determined by echocardiography and inva-
sive hemodynamics. 
In a separate experiment we assessed the effect of inhibi-
tion of cellular respiration. To this end a group of 16 week-
old ApoE
-/- mice were treated for 4-6 weeks with the mild 
thiol-blocking agent cystamine (300 mg/kg/d). After 4-6 
weeks of treatment, heart function was measured by echo-
cardiography. At the end of the observation period, all mice 
were anesthetized, and after intracardial perfusion with   
sterile PBS, hearts were rapidly isolated, and processed for 
further use. 
All animal experiments were performed in accordance 
with the NIH guidelines and reviewed and approved by   
the local committees on animal care and use (University of 
Zurich and Hamburg).  
Echocardiography and Invasive Hemodynamics 
Transthoracic echocardiography was performed on anes-
thetized mice with a Vivid 7 echocardiograph equipment 
(GE Healthcare) and a 12 MHz linear array transducer. Left 
ventricular dimensions, and fractional shortening were ob-
tained in the parasternal long axis view using M-mode imag-
ing according to the recommendations of the American Soci-
ety of Cardiology [12]. Ejection fraction (EF) was calculated 
using the formula of Teichholz. Recordings were interpreted 
off-line using EchoPac Pc 3.0 software (GE) 
At the end of the observation period invasive hemody-
namic measurements were performed in anesthetized mice. 
A 1.4 French Millar catheter (Millar Instruments) was   
inserted into the right carotid artery and advanced into the 
ascending aorta and the left ventricle under continuous moni-
toring of the pressure waveform. Arterial and left ventricular 
pressures were recorded and analyzed with a PowerLab   
system (ADI Instruments). 
Microarray Gene Expression Analysis 
Whole genome microarray gene expression analysis of 
cardiac tissue was performed essentially as described previ-
ously [13]. Briefly, total RNA of heart tissue was isolated 
with the RNeasy Midi kit (Qiagen). Procedures for cDNA 
synthesis, labeling and hybridization were carried out ac-
cording to the protocol of the manufacturer (Affymetrix). 
For hybridization, 15 μg of fragmented cRNA were incu-
bated with the chip (Affymetrix GeneChip Mouse genome 
MG430 2.0 Array) in 200 μl of hybridization solution in a 
Hybridization Oven 640 (Affymetrix) at 45 °C for 16 h. 
GeneChips were washed and stained using the Affymetrix 
Fluidics Station 450 according to the GeneChip Expression 
Analysis Technical Manual (Rev. 5). Microarrays were 
scanned with the Affymetrix GeneChip Scanner 7G, and the 
signals were processed with a target value of 300 using 
GCOS (v. 1.4, Affymetrix). All microarray gene expression 
data are available at NCBI GEO database accession   
no. GSE25765-8 (GSE25765, GSE25766, GSE25767, 
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Antibodies 
The following antibodies were used for immunohisto-
chemistry, immunofluorescence, and immunoblotting: rabbit 
anti-FASN antibodies, which were raised against an antigen 
encompassing amino acids 2205-2504 of human fatty acid 
synthase (FASN); rabbit anti-Scd1 antibodies, which were 
raised against the amino terminal region of mouse stearoyl-
Coenzyme A desaturase 1 (Scd1); rabbit anti-SCD1 antibod-
ies, which were raised against an antigen encompassing 
amino acids 21-51 of human SCD1; mouse monoclonal anti-
body raised against -sarcomeric actin (A2172 clone 5C5, 
Sigma); rabbit anti-NPPA antibodies, which were raised 
against an epitope encompassing amino acids 1-153 of hu-
man natriuretic peptide type A (NPPA); rabbit anti-
Ucp1/UCP1 antibodies, which were raised against antigens 
encompassing amino acids 288-302 of mouse/human uncou-
pling protein 1 (Ucp1/UCP1); rabbit anti-resistin antibodies, 
which were raised against recombinant human resistin 
(RETN); rabbit anti-GAPDH antibodies, which were raised 
against amino acids 1-335 of human glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Immunoblotting and 
immunohistochemistry were routinely used to determine and 
confirm cross-reactivity of the antibodies with the respective 
mouse and human proteins. 
Functional Assays 
Total cardiac lipids were extracted from pulverized fro-
zen cardiac tissue by the method of Folch et al. [14]. Myo-
cardial triglyceride content was quantified using an enzy-
matic spectrophotometric kit according to the manufacturer`s 
instructions (Sigma). Lipid synthesis was determined with 
cardiomyocytes incubated with 1,2-[
14C]-acetate (57 mCi/ 
mmol; 3 μCi/dish) added to the culture medium. After 4 h of 
incubation at 37 °C, cells were washed with PBS, 
trypsinized, collected by centrifugation and resuspended in 
0.8 ml PBS. Lipids were extracted as described above, and 
incorporation of 1,2-[
14C]-acetate into lipids was quantified 
by scintillation counting. Neonatal rat cardiomycytes were 
isolated and transfected as described [15]. DNA strand 
breaks were determined by the terminal deoxynucleotidyl 
transferase-mediated dUTP nick-end labeling (TUNEL) 
technique (Roche Applied Science) essentially as detailed 
previously [16]. Caspase-3 activity was measured using a 
commercially available caspase-3 assay kit (Clontech). 
Measurement of [ATP] of cardiac tissue extracts was per-
formed with a luciferase enzyme kit according to the manu-
facturer`s instructions (Invitrogen). 
Immunohistology 
For immunohistology, paraffin sections or cryosections 
of mouse or human heart specimens were used. Immuno- 
histological detection of Fasn (FASN), Ucp1 (UCP1),   
and Scd1 (SCD1) was performed with affinity-purified, 
polyclonal antibodies similarly as described [13, 17]. Oil   
red O staining was performed on frozen heart sections   
and on isolated aortas as described [13]. All sections were 
imaged with a Leica DMI6000 microscope equipped with   
a DFC420 camera. 
Immunofluorescence 
Immunofluorescence localization studies were performed 
with cryosections (10 μm) of post-fixed and frozen hearts 
obtained from 10 month-old mice with 6 months of AAC. 
For co-localization of Fasn and -sarcomeric actin, affinity-
purified rabbit anti-Fasn antibodies and mouse anti--
sarcomeric actin antibodies were applied (dilution 1:4000), 
followed by secondary antibodies or F(ab)2 fragments of the 
antibodies labeled with Alexa Fluor 546 and Alexa Fluor 
488, respectively (dilution 1:5000), and counterstaining with 
DAPI. Sections were imaged with a Leica (TCS) confocal 
laser microscope. 
Immunoblotting 
Immunoblot detection of proteins was performed with af-
finity-purified antibodies or F(ab)2 fragments of the respec-
tive antibodies [13]. Bound antibody was visualized with 
F(ab)2 fragments of enzyme-coupled secondary antibodies, 
or by enzyme-coupled protein A, as applicable, followed by 
enhanced chemiluminescence detection. 
Patients 
Small myocardial biopsy specimens were obtained from 
nine patients (age 59±13 years) undergoing mitral valve re-
placement. Five patients had congestive heart failure (NYHA 
class III-IV). Informed consent was obtained from all par-
ticipants. The study was conducted in conformity with the 
principles of the declaration of Helsinki, with approval of the 
protocol by the ethical committee of Ain Shams University. 
Statistical Analyses 
Results are presented as mean ± S. D. unless specified 
otherwise. Unpaired or paired Student t tests were used to 
compare results between two groups. Statistical significance 
was set at a p value of < 0.05, unless indicated differently. 
RESULTS 
Chronic Pressure Overload Induces Signs of Heart Fail-
ure in B6 Mice 
Chronically elevated blood pressure is a major causative 
factor for the development of cardiac hypertrophy culminat-
ing finally in heart failure [18]. To analyze mechanisms un-
derlying the transition from cardiac hypertrophy to heart 
failure we used an experimental model of chronic pressure 
overload induced by abdominal aortic constriction (AAC). In 
agreement with previous studies [19], echocardiography 
showed that 1 month of aortic constriction did not signifi-
cantly impair the cardiac function of B6 mice compared to 
sham-operated controls (Fig. 1A). In contrast, after 6 months 
of chronic pressure overload, B6 mice showed signs of heart 
failure as evidenced by the strongly reduced ejection fraction 
of 28.8 ± 3.3 % (Fig. 1A, *p<0.0003 vs. sham-operated, age-
matched B6 mice). 
As demonstrated by others [19], 1 month of aortic con-
striction induced cardiac hypertrophy in B6 mice (Fig. 1B, 
middle vs. left panel). However, after 6 months of pressure 
overload, histological analysis demonstrated that hearts of   
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B6 mice with signs of heart failure were characterized by 
cardiac hypertrophy with dilation (Fig. 1B, right vs. middle 
and left panel). 
In addition to dilated cardiac hypertrophy, invasive 
hemodynamics demonstrated the severe impairment of heart 
function after 6 months of AAC. While the peak left ven-
tricular systolic pressure was not altered in mice with severe 
cardiac dilation (Fig. 1C, right vs. left panel), there was a 
significant decrease in the maximum rate of change of left 
ventricular pressure, dP/dtmax, after 6 months of AAC com-
pared to sham-operated controls (Fig. 1D, right vs. left 
panel). For comparison, mice with 1 month of AAC showed 
a significantly increased peak left ventricular systolic pres-
sure whereas the maximum rate of change of left ventricular 
pressure was maintained relative to sham-operated control 
mice (Fig. 1C,D, left panels). 
As an additional control, 1 month of AAC induced a sig-
nificant rise in cardiac protein levels of the hypertrophic 
marker, natriuretic peptide type A (Nppa). In contrast, Nppa 
levels returned to baseline after 6 months of AAC during the 
transition to heart failure (Fig. 1E, upper panel, and Fig. 1F; 
and ref. [20]). 
To further analyze the development of signs of heart fail-
ure induced by 6 months of AAC, cardiac resistin was de-
termined because resistin may serve as an indicator of heart 
failure in patients [21]. Quantitative immunoblotting re-
vealed that cardiac resistin protein levels were significantly 
higher in mice with signs of heart failure whereas resistin 
was not different from control mice after 1 month of AAC 
(Fig. 1E, middle panel, and Fig. 1G). Immunohistology con-
firmed the increased resistin protein levels in the hypertro-
phic myocardium with dilation after 6 months of aortic con-
striction while resistin was not significantly increased in the 
hypertrophic heart after 1 month of AAC compared to sham-
operated controls (Fig. 1H, right vs. middle and left panel). 
Together the data indicate that 6 months of AAC induced 
signs of heart failure with dilated cardiac hypertrophy in B6 
mice. 
Pressure Overload Accelerates the Development of Heart 
Failure in Atherosclerosis-Prone ApoE
-/- Mice 
In addition to pressure overload, atherosclerosis is an-
other major etiologic factor for the development of heart 
failure [22, 23]. To analyze the impact of atherosclerosis on 
the development of heart failure induced by chronic pressure 
overload, aortic constriction was performed in atherosclero-
sis-prone ApoE
-/- mice. In contrast to B6 mice (cf. Fig. 1), 2 
months of pressure overload were sufficient to induce signs 
of heart failure in ApoE
-/- mice (Fig. 2A). After 2 months of 
aortic constriction, the ejection fraction of ApoE
-/- mice was 
reduced to 28.1 ± 2.9 % (*p<0.0001 vs. sham-operated B6 or 
ApoE
-/- mice). As a control, the cardiac function was not 
significantly different between sham-operated 6 month-old 
B6 and ApoE
-/- mice (Fig. 2A, B). 
Concomitantly to signs of heart failure, echocardiography 
showed left ventricular dilation in ApoE
-/- mice after two 
months of aortic constriction (Fig. 2B). The left ventricular 
end diastolic diameter was 7.2 ± 0.2 mm, 5.9 ± 0.3 mm and 
6.1 ± 0.3 mm of aortic-constricted ApoE
-/-, B6 and sham-
operated ApoE
-/- mice, respectively (n=6 mice per group, 
*p<0.0002 between aortic-constricted ApoE
-/-, and B6 or 
sham-operated ApoE
-/- mice). 
Histological analysis of hematoxylin- and eosin-stained 
heart sections confirmed that two months of pressure over-
load had induced cardiac hypertrophy with dilation in ApoE
-
/- mice compared to sham-operated control mice (Fig. 2C, 
left vs. right panel). 
In addition to the strongly reduced ejection fraction there 
was a significant reduction in the maximum rate of change of 
left ventricular pressure (dP/dtmax) upon two months of AAC 
relative to sham-operated ApoE
-/- mice, as determined by 
invasive hemodynamics (Fig. 2D). Moreover, the peak left 
ventricular systolic pressure of aortic-constricted ApoE
-/- 
mice with dilated cardiac hypertrophy was comparable to the 
left ventricular systolic pressure of sham-operated controls 
(Fig. 2E). Together these data show that two months of pres-
sure overload had induced signs of heart failure in ApoE
-/- 
mice. 
Aged ApoE
-/- Mice Develop Signs of Heart Failure and 
Dilated Cardiac Hypertrophy 
Chronic atherosclerosis is a primary etiologic risk factor 
for the development of heart failure in patients [22, 23]. 
However, the relationship between atherosclerosis and the 
development of heart failure in an animal model of athero-
sclerosis is not established. To analyze the impact of athero-
sclerosis on heart function, we used aged ApoE
-/- mice. With 
increasing age, ApoE
-/- mice developed a high atheroscle-
rotic plaque load in the aorta (Fig. 3A). At an age of 18 
months, the transverse aorta of ApoE
-/- mice was almost 
completely covered with atherosclerotic plaques (Fig. 3A, 
right vs. middle and left panel). The aortic surface area cov-
ered with lesions was 8.0 ± 2.4 %, 24.2 ± 4.9 % and 88.0 ± 
4.2 % of 3, 8 and 18 month-old ApoE
-/- mice, respectively, 
as determined by quantitative image analysis of oil red O 
stained aortas (n = 5 mice/group). 
We asked whether the development of atherosclerotic 
plaques in the aorta affected the cardiac function of ApoE
-/- 
mice. Echocardiography showed that the increase in athero-
sclerotic plaque area was accompanied by a strongly reduced 
ejection fraction (Fig. 3B). At an age of 18 months, the ejec-
tion fraction of ApoE
-/- mice was 29.7 ± 2.9 % whereas age-
matched C57BL/6J (B6) control mice had an ejection frac-
tion of 54.0 ± 4.7 % (Fig. 3B). Invasive hemodynamics fur-
ther confirmed the impaired cardiac function of 18 month-
old ApoE
-/- mice. The maximum rate of change of left ven-
tricular pressure (dP/dtmax) was significantly reduced of 
ApoE
-/- mice relative to age-matched B6 mice (Fig. 3C). 
Concomitantly, there was a significant increase in the left 
ventricular end-diastolic pressure (Fig. 3D) while the peak 
left ventricular systolic pressure was not significantly differ-
ent between 18 month-old ApoE
-/- and B6 control mice (Fig. 
3E). 
In addition to the impaired cardiac function, hearts of 18 
month-old ApoE
-/- mice with high atherosclerotic plaque 
load displayed signs of dilated cardiac hypertrophy as deter-
mined by histological analysis of hematoxylin/eosin (HE)-
stained sections (Fig. 3F). The heart weight to body weight 194    Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011, Vol. 9, No. 3  AbdAlla et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Chronic pressure overload induces signs of heart failure in B6 mice. A. The ejection fraction of 5 month-old and 10 month-old B6 
mice with 1 month and 6 months of abdominal aortic constriction (B6-AAC), respectively, was determined by echocardiography relative to 
age-matched sham-operated controls (B6-sham). Abdominal aortic constriction (AAC) was performed with 4 month-old (i.e. 16 week-old) 
mice. Age of mice is given in weeks. Data represent mean ± S.D., n=4 mice/group (***, p<0.0003). B. Representative hematoxylin-eosin 
(HE)-stained heart sections from a 5 month-old (middle) and 10 month-old (right) B6 mouse isolated after 1 month (1mo AAC) and 6 months 
(6mo AAC) of AAC, respectively. The sham-operated control (left, Sham) is a 10 month-old mouse (bar: 2 mm). C, D. Cardiac function pa-
rameters were determined by invasive hemodynamics of 5 month-old (left) and 10 month-old (right) B6 mice. The peak left ventricular sys-
tolic pressure (LVSP; C), and the maximum rate of change of left ventricular pressure (dP/dtmax; D) were determined in B6 mice after 1 month 
(AAC 1mo) and 6 months (AAC 6mo) of AAC, respectively, relative to age-matched, sham-operated controls (Sham). Data represent mean ± 
S.D., n=4 mice/group (***, p<0.0004). E-G. Panel E shows the immunoblot detection of natriuretic peptide type A (IB: anti-Nppa), resistin 
(IB: anti-Resistin) and Gapdh (IB: anti-Gapdh) in heart tissue isolated from 5 month-old B6 mice after 1 month of AAC (1mo AAC) and from 
10 month-old B6 mice after 6 months of AAC (6mo AAC), respectively. The sham controls were obtained from 10 month-old mice (Sham). 
Quantification of Nppa protein levels by densitometric immunoblot scanning is shown in F, and panel G shows the immunoblot quantifica-
tion of resistin protein levels. Data represent mean ± S. D., n=4 mice/group (*, p<0.01; 6 months of AAC vs. 1 month of AAC). H. Immuno-
histology detection of resistin with anti-resistin antibodies (anti-Resistin) on frozen heart sections of sham-operated B6 mice (Sham, age 10 
months), 5 month-old B6 mice with 1 month of AAC (1mo AAC) and 10 month-old B6 mice with 6 months of AAC (6mo AAC). Nuclei 
were stained with hematoxylin (bar: 40 μm). As specificity control, pre-absorption of the antibodies with the antigen used for immunization 
(preabsorption cont.) was performed. Histology data are representative of at least 3 different mice per group (B, H). 
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Fig. (2). Pressure overload accelerates the development of heart failure in ApoE
-/- mice. A. Ejection fraction of 6 month-old ApoE
-/- mice 
after 2 months of abdominal aortic constriction (ApoE
-/- AAC) relative to age-matched B6 mice (B6) and sham-operated ApoE
-/- mice (ApoE
-
/- sham) was determined by echocardiography (***, p<0.0001, n=6). B. Representative echocardiograms of a 6 month-old ApoE
-/- mouse after 
2 months of AAC (ApoE
-/- AAC; left panels), an age-matched B6 mouse (B6; middle panels), and a 6 month-old, sham-operated ApoE
-/- 
mouse (ApoE
-/- sham; right panels) in B-mode (upper panels) and M-mode (lower panels). C. Representative hematoxylin-eosin (HE)-stained 
heart sections of a 6 month-old ApoE
-/- mouse with 2 months of AAC (2mo AAC; left panel) and a 6 month-old sham-operated ApoE
-/- con-
trol mouse (Sham; right panel). Histology data are representative of at least 3 different mice per group (bar: 2 mm). D, E. Cardiac function 
parameters were determined by invasive hemodynamics of 6 month-old ApoE
-/- mice after 2 months of AAC (ApoE
-/- AAC) and of sham-
operated ApoE
-/- controls (ApoE
-/- sham). The maximum rate of change of left ventricular pressure (dP/dtmax; D), and the peak left ventricular 
systolic pressure (LVSP; E) are shown. Data represent mean ± S.D., n=4 mice/group (**, p<0.0004). 
ratio was also significantly increased (Fig. 3G), and cardio-
myocyte hypertrophy was visible by an increased cell size 
and nuclear size of hypertrophied cardiomyocytes compared 
to B6 controls (Fig. 3H). Altogether, the data reveal a 
strongly impaired heart function and signs of heart failure in 
aged ApoE
-/- mice with advanced atherosclerosis. 
Microarray Gene Expression Profiling Demonstrates   
Up-Regulation of the Cardiac Lipid Metabolism at the 
Onset of Heart Failure 
To identify genes specifically up-regulated at the onset of 
heart failure we performed a whole genome microarray gene 
expression study with cardiac tissue from the three experi-
mental models of heart failure. After data normalization, 
microarray data were subjected to stringent data filtering 
according to the following criteria: (i) significant difference 
from the respective control group (*p<0.01), (ii) more than 
two-fold up-regulation relative to control values, and (iii) 
involvement in lipid metabolism according to the literature. 
We focused on proteins involved in lipid synthesis and me-
tabolism because metabolic dysfunction is a key feature of 
the failing heart, and serum levels of free fatty acids are in-
creased in the course of heart failure in patients [2, 6]. 
Moreover, excessive triglyceride and lipid accumulation is a 
characteristic pathologic feature of failing and ischemic heart 
tissue [24, 25]. With those stringent criteria, 11 fat metabo-
lism genes were identified, which are essentially involved in 
lipid synthesis, storage and oxidation (Fig. 4A). Notably, 
those 11 genes were similarly up-regulated in the three dif-
ferent models of heart failure where heart failure was in-
duced by pressure overload or advanced atherosclerosis (Fig. 
4A, left, middle, right panels). As a control, the cardiac lipid 
metabolism gene cluster was not induced by hypercholes-
terolemia because expression of the lipid metabolism genes 
was not different between young ApoE
-/- m i c e  ( a g e  2 4  
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weeks, without heart failure signs) and age-matched B6 mice 
(Fig. 4A, middle panel). 
Specifically, the microarray approach showed up-
regulation of key enzymes of fatty acid synthesis, i.e. Fasn 
(fatty acid synthase), Scd1, Scd2 (stearoyl-Coenzyme A de-
saturase 1 and 2), and Elovl6 (long chain fatty acid elongase 
6). Two up-regulated genes are known to increase the supply 
of acetyl CoA/acetoacetyl CoA as primers of fatty acid syn-
thesis, i.e. Ctp (citrate transport protein) and Aacs (acetoace-
tyl-Coenzyme A synthase). And Cidea and Cidec (cell death-
inducing DNA fragmentation factor, alpha subunit-like ef-
fector A and C) stimulate the storage of lipids in lipid drop-
lets. In addition to enzymes stimulating fatty acid synthesis 
and storage, another group of up-regulated genes is involved 
in mitochondrial fatty acid oxidation: Acly (ATP citrate 
lyase), Acsm3 (acyl-CoA synthetase medium chain family 
member 3) and Ucp1 (uncoupling protein 1).  
The up-regulation of the cardiac lipid metabolism was re-
lated to the onset of heart failure signs, because hypertrophic 
heart tissue isolated from B6 mice after 1 month of AAC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Aged ApoE
-/- mice develop signs of heart failure and dilated cardiac hypertrophy. A. Detection of atherosclerotic plaques in the 
aorta of ApoE
-/- mice (ApoE
-/-) by oil red O staining. Aortas were isolated at 3, 8 and 18 months (mo) of age. B. The ejection fraction was 
determined by echocardiography of 3, 8, 12 and 18 month-old ApoE
-/- mice relative to B6 mice (± S. D., n=4; **, p<0.0002; ApoE
-/- vs. age-
matched B6 mice). C-E. Cardiac function parameters of 18 month-old ApoE
-/- mice were determined by invasive hemodynamics. Panel C 
shows the maximum rate of change of left ventricular pressure (dP/dtmax). Panels D and E present the left ventricular end-diastolic pressure 
(LVEDP; D) and the peak left ventricular systolic pressure (LVSP; E) of 18 month-old ApoE
-/- mice (ApoE
-/-) relative to age-matched B6 
control mice (± S. D.; n=4; **, p<0.002). F. Hematoxylin-eosin (HE) stained heart sections of an 18 month-old ApoE
-/- (left panel) and an 
age-matched control B6 mouse (right panel); bar: 2 mm. G. Increased heart weight to body weight ratio (HW/BW) of 18 month-old (18mo) 
ApoE
-/- mice relative to age-matched B6 mice (±S.D., n=4; **, p<0.0002). H. Hematoxylin eosin (HE)-stained heart sections of an 18 
month-old ApoE
-/- mouse and an age-matched control mouse (bar: 40 μm). Histology data are representative of at least 3 different mice per 
group (A, F, H). 
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without signs of heart failure (cf. Fig. 1) did not show a   
significant change in the expression of lipid metabolism 
genes, although the hypertrophic marker, natriuretic peptide 
type B (Nppb), was increased (Fig. 4B). As controls, the 
heart failure-related protein, resistin (Retn), was specifically 
up-regulated in aortic-constricted mice with signs of heart 
failure (Fig. 4A, left and middle panel; Fig. 4B) while ApoE 
was only expressed in B6 mice (Fig. 4A). Thus, the micro- 
array approach revealed the strong up-regulation of major fat 
metabolizing enzymes in hearts of mice with signs of heart 
failure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Up-regulation of the cardiac lipid metabolism at the onset of heart failure. A. Microarray gene expression analyses of heart tissue from 
three different models of heart failure were compared to respective controls: (i) 10 month-old B6 mice with 6 months of AAC (B6 AAC-6m) 
relative to 10 month-old, sham-operated B6 controls (B6 sham), (ii) 6 month-old ApoE
-/- mice with 2 months of AAC (Apoe
-/- AAC) relative to 
age-matched, sham-operated ApoE
-/- controls (Apoe
-/- sham), and (iii) 18 month-old ApoE
-/- mice (Apoe
-/- 18 mo) relative to 18 month-old B6 
controls (B6 18mo). As an additional control for ApoE
-/- AAC model, age-matched B6 mice (B6) are shown. Normalized signal intensity values 
of differentially expressed probe sets detecting fat metabolism genes are presented as heat map centered to the median value. Probe sets, which 
showed (i) a significantly different signal intensity value relative to the respective controls (*, p<0.01), (ii) a more than 2-fold up-regulation rela-
tive to the respective controls, and (iii) involvement in fat metabolism are listed. Probe sets detecting genes involved in lipid synthesis (Synthe-
sis), storage (Stor.) and oxidation (Oxidat.) are shown. As controls, the probe sets detecting resistin (Retn) and ApoE (Apoe) were included. B. 
Microarray gene expression analysis data showed up-regulation key fat metabolism genes in failing cardiac tissue isolated from 10 month-old B6 
mice after 6 months of AAC (Cardiac Failure; AAC-6mo) whereas the expression of fat metabolism genes was normal in 5 month-old B6 mice 
after 1 month of AAC (Cardiac Hypertrophy; AAC-1mo) inducing cardiac hypertrophy without failure (cf. Fig. 1). Gene expression is presented 
as fold change relative to the respective age-matched, sham-operated B6 control (-fold of B6; *, p<0.01). 
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Myocardial Fatty Acid Synthase Protein in Failing 
Hearts 
In agreement with the microarray data, fat metabolizing 
proteins identified by the microarray approach were local-
ized in cardiac tissue of failing hearts as exemplified for the 
essential fat synthesizing enzyme, fatty acid synthase (Fasn) 
(Fig. 5A, upper panels; and cf. Fig. 6C, D). High protein 
levels of Fasn were detected by immunohistology on heart 
sections of three different models of heart failure (Fig. 5A, 
upper panels). For comparison, protein levels of Fasn   
were low in cardiac tissue from control mice (Fig. 5A, lower 
panels). 
Co-localization studies with the cardiomyocyte-specific 
marker,  -sarcomeric actin, confirmed localization of up-
regulated Fasn in cardiomyocytes (Fig. 5B).  
Increased Cardiac Triglyceride Content and Cell Death 
in Mice with Signs of Heart Failure 
Concomitantly to increased levels of lipid synthesizing 
enzymes, the cardiac triglyceride content was significantly 
increased in B6 mice with signs of heart failure induced by 6 
months of AAC (Fig. 5C). In contrast, cardiac triglycerides 
after 1 month of AAC were not significantly different from 
sham-operated control mice (Fig. 5C). Thus, the onset of 
heart failure in B6 mice was accompanied by the up-
regulation of the cardiac lipid metabolism and the accumula-
tion of cardiac lipids.  
Failing hearts of patients are characterized by increased 
cardiomyocyte apoptosis [26], and accumulation of lipids is 
considered toxic to the heart [25, 27]. To determine whether 
accumulation of cardiac triglycerides was accompanied by 
an increase in cardiomyocyte cell death, quantification of 
cell nuclei with DNA strand breaks as a marker of cell death 
was performed in situ by TUNEL technology. The number 
of TUNEL-positive cell nuclei was significantly increased in 
cardiac tissue of B6 mice with signs of heart failure triggered 
by 6 months of AAC compared to B6 mice with 1 month of 
AAC (Fig. 5D). As a control, TUNEL-positive cells were 
almost undetectable in sham-operated control mice (Fig. 
5D). Altogether, heart failure signs in B6 mice correlated 
with the accumulation of cardiac triglycerides and an in-
crease of DNA-strand breaks as a marker of cardiomyocyte 
cell death. 
Lipids are Toxic to Isolated Cardiomyocytes 
Accumulation of lipids is considered toxic to the heart by 
enhancing cardiomyocyte cell death [25, 27]. In agreement 
with that notion, incubation of isolated cardiomyocytes for 
18 h with 0.5 mM palmitic acid increased cardiomyocyte cell 
death as visible by more than 2.5-fold increased levels of 
TUNEL-positive cells with DNA strand breaks relative to 
control cells (Fig. 5E). 
Palmitic acid comprises more than 90 % of fatty acids 
synthesized by Fasn [28]. Therefore we asked whether the 
increased expression of Fasn in cardiomyocytes also trig-
gered DNA strand breaks as a marker of cardiomyocyte cell 
death. Isolated cardiomyocytes were transfected with a 
plasmid encoding Fasn, and DNA strand breaks were deter-
mined. The TUNEL assay showed that cardiomyocyte death 
was also strongly increased by the expression of Fasn (Fig. 
5F). As a control, Fasn protein levels were increased ~3.1-
fold by transfection of Fasn as determined by immunoblot 
with Fasn-specific antibodies (Fig. 5G). Concomitantly, the 
lipogenic activity of cardiomyocytes was increased 3.3-fold 
(Fig. 5H). Together the data show that fatty acid overload 
increased markers of cardiomyocyte death.  
Anti-Ischemic Treatment with Ranolazine Normalized 
the Cardiac Lipid Metabolism at the Onset of Heart 
Failure 
Accumulation of lipids was linked to oxygen deprivation 
[25], which may be triggered by the high myocardial oxygen 
consumption of failing hearts to meet the increased ATP 
demand [2, 3]. To analyze whether up-regulation of the car-
diac lipid metabolism at the onset of heart failure was also 
related to insufficient oxygen supply, treatment was per-
formed with an anti-ischemic drug, ranolazine [29]. The ef-
fect of ranolazine was analyzed in two experimental models 
of heart failure, i.e. 10 month-old B6 mice with 6 months of 
chronic pressure overload and 18 month-old ApoE
-/- mice 
with advanced atherosclerosis. Microarray gene expression 
analysis showed that ranolazine treatment for two months 
normalized the up-regulated fat metabolism of failing B6 
hearts with 6 months of AAC-induced pressure overload as 
exemplified for probe sets detecting Scd1, Fasn, and Ucp1 
(Fig. 6A). Ranolazine specifically affected the fat metabo-
lism whereas the expression of another metabolic enzyme, 3-
hydroxybutyrate dehydrogenase type 1 (Bdh1) was not sig-
nificantly reduced by ranolazine (Fig. 6A). 
The microarray analysis also demonstrated that rano-
lazine reduced the up-regulated fat metabolism of 18 month-
old ApoE
-/- mice with heart failure (Fig. 6B). Again, the 
AAC-induced up-regulation of Bdh1 was not significantly 
affected by ranolazine treatment (Fig. 6B). 
Immunohistological detection of fat metabolizing en-
zymes Scd1 and Fasn on heart sections of untreated and ra-
nolazine-treated B6 mice with 6 months of AAC confirmed 
the down-regulation of key fat synthesizing enzymes by ra-
nolazine (Fig. 6, upper and middle panels). Similarly, immu-
nohistology also demonstrated the ranolazine-induced nor-
malization of Scd1 and Fasn protein levels in heart tissue of 
aged ApoE
-/- mice (Fig. 6D, upper and middle panels). In 
addition to fat synthesizing enzymes, ranolazine also normal-
ized the expression and protein levels of the fat oxidizing 
enzyme, Ucp1, in failing hearts of B6 mice with chronic 
pressure overload and ApoE
-/- mice with advanced athero-
sclerosis (Fig. 6A,B and Fig. 6C,D, lower panel). Thus, the 
anti-ischemic drug ranolazine normalized the increased lipid 
metabolism in two different experimental models of heart 
failure. 
Anti-Ischemic Treatment Reduced Cardiac Lipid Over-
load and Cardiomyocyte Apoptosis 
Concomitantly to the normalization of fat metabolizing 
enzymes, ranolazine also strongly reduced the cardiac 
triglyceride content of the two different models of heart fail-
ure (Fig. 6E). The reduced cardiac lipid load was accompa-
nied by a decreased cardiomyocyte cell death as detected by 
the normalized activity of the apoptosis effector caspase-3 in Cardiac Lipid Metabolism in Heart Failure  Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011, Vol. 9, No. 3    199 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Myocardial fatty acid synthase, lipid accumulation and cell death. A. Immmunohistology detection of Fasn with anti-Fasn antibodies 
(Fasn) on frozen heart sections of three different heart failure models (upper panels), i.e. 10 month-old B6 mice with 6 months of AAC (B6 
AAC-6mo), 6 month-old ApoE
-/- mice with 2 months of AAC (ApoE
-/- AAC), and 18 month-old ApoE
-/- mice (ApoE
-/--18 mo). Age-matched, 
10 month-old sham-operated B6 mice (B6 sham), 6 month-old sham-operated ApoE
-/- mice (ApoE
-/- sham) and 18 month-old B6 mice (B6-18 
mo) served as controls (lower panels; bar: 40 μm). B. Immunofluorescence co-localization of Fasn with -sarcomeric actin on frozen heart 
sections of a 10 month-old B6 mouse with 6 months of AAC (B6 AAC-6mo). -sarcomeric actin was detected with affinity-purified, mouse 
anti-actin antibodies followed by F(ab)2 fragments of Alexa Fluor 488-labeled (green) secondary antibodies (upper left/right panels). The 
actin-positive cardiomyocytes co-localized with Fasn, which was detected with affinity-purified, rabbit anti-Fasn antibodies followed by 
F(ab)2 fragments of Alexa Fluor 546-labeled (red) secondary antibodies (upper left/lower right panels). Cell nuclei were stained with DAPI 
(blue, left panels; bar: 20 μm). Immunohistology (A) and immunofluorescence (B) data are representative of at least 3 different mice/group. 
C. Cardiac triglyceride content (μmol/g wet weight) was determined with 5 month-old B6 mice after 1 month of AAC (AAC-1mo) and 10 
month-old B6 mice after 6 months of AAC (AAC-6mo). Age-matched sham-operated B6 mice served as controls (Sham-1mo; Sham-6mo). 
Data represent mean ± S.D., n=4 mice/group (**, p<0.001; 6 months of AAC vs. 1 month of AAC). D. The number of TUNEL-positive car-
diomyocytes (per 10
4 cells) was determined by an in situ cell death detection (TUNEL) assay on formalin-fixed, paraffin-embedded heart 
sections of 5 month-old B6 mice after 1 month of AAC (AAC-1mo) and 10 month-old B6 mice after 6 months of AAC (AAC-6mo). Age-
matched, sham-operated B6 mice served as controls (Sham-1mo; Sham-6mo). Data represent mean ± S. D., n=4 mice/group (**, p<0.001; 6 
months of AAC vs. 1 month of AAC). E, F. Percentage (%) of TUNEL-positive cardiomyocytes was determined (E) with isolated neonatal 
cardiomyocytes incubated with 0.5 mM palmitic acid/BSA for 18 h (+Palmitate) relative to control cells (Cont.), and (F) with isolated car-
diomyocytes over-expressing Fasn (+Fasn) relative to mock-transfected control cardiomyocytes (Cont.). Data represent mean ± S.D., n=3 
different experiments performed in triplicates each (**, p<0.0001 and *, p<0.005). G. Over-expression of Fasn in transfected cardiomyocytes 
(+Fasn) was detected in immunoblot with Fasn-specific antibodies (IB: anti-Fasn) relative to mock-transfected cells (Cont.). The lower panel 
is a control immunoblot detecting actin (IB: anti-actin). H. Transfected cardiomyocytes expressing Fasn show increased lipogenic activity 
relative to mock-transfected controls. Lipogenic activity was determined by incorporation of 1,2-[
14C]-acetate into lipids and is expressed as 
d.p.m. per well. Data represent mean ± S. D., n=3 different experiments performed in triplicates each (**, p<0.0005). 
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Fig. (6). Anti-ischemic treatment with ranolazine normalized the cardiac lipid metabolism and cardiac function of mice with signs of heart failure. A, 
B. The effect of 2 months of ranolazine treatment (Treated) on the expression of lipid metabolism genes was determined by microarray analysis of 
hearts isolated from 10 month-old B6 mice with 6 months of AAC (A, AAC-B6; Untreated vs. Treated), and 18 month-old ApoE
-/- mice with ad-
vanced atherosclerosis (B, ApoE
-/--18mo; Untreated vs. Treated). Gene expression is presented as fold change relative to the respective control, i.e. 
untreated 10 month-old sham-operated B6 mice (A, -fold of sham), and untreated 18 month-old B6 mice (B, -fold of B6); *, p<0.01. C, D. Immuno-
histological detection of Scd1 (upper panels), Fasn (middle panels) and Ucp1 (lower panels) was performed with the respective antibodies on heart 
sections of untreated (Untreated; left panels) and ranolazine-treated (Treated; right panels) 10 month-old B6 mice after 6 months of AAC (C, AAC-
B6), and 18 month-old ApoE
-/- mice (D, ApoE
-/--18mo). Histology data are representative of at least 3 different mice/group (bar: 40 μm). Nuclei were 
stained with hematoxylin (upper panels). E. Cardiac triglyceride content was determined with hearts isolated from untreated (Untreated) and rano-
lazine-treated (Treated) 10 month-old B6 mice after 6 months of AAC (AAC-B6; left panel), and 18 month-old ApoE
-/- mice (ApoE
-/--18mo; right 
panel). As controls, 10 month-old, sham-operated B6 mice (Sham, left panel), and 18 month-old B6 mice (B6, right panel) were included. Data repre-
sent mean ± S. D., n=4 mice/group (**, p<0.001; *, p<0.01). F. Caspase-3 activity (Casp-3 activity) as a marker of apoptotic cell death was deter-
mined with hearts isolated from untreated (Untreated) and ranolazine-treated (Treated) 10 month-old B6 mice after 6 months of AAC (AAC-B6; left 
panel), and 18 month-old ApoE
-/- mice (ApoE
-/--18mo; right panel). Data are expressed as percentage of the respective control (set to 100 %), i.e. 10 
month-old sham-operated B6 mice (Sham, left panel), and 18 month-old B6 mice (B6, right panel), and represent mean ± S. D., n=4 mice/group (**, 
p<0.001). G. The ejection fraction of untreated (Untreated) and ranolazine-treated (Treated) 10 month-old B6 mice with 6 months of AAC (AAC-B6) 
was determined by echocardiography. Untreated, sham-operated 10 month-old B6 mice (Sham) served as controls. Data represent mean ± S. D., n=4 
mice/group (**, p<0.0005; *, p<0.01). H. The ejection fraction (expressed in %) of untreated (Untreated) and ranolazine-treated (Treated) 18 month-
old ApoE
-/- mice (ApoE
-/--18mo). Untreated 18 month-old B6 mice (B6) served as controls. Data represent mean ± S. D., n=4 mice/group (**, 
p<0.001; *, p<0.01). I. Ranolazine-treatment (Treated; right panel) for two months did not significantly affect the atherosclerotic plaque load in the 
aorta of 18 month-old ApoE
-/- mice (Aorta; ApoE
-/--18mo) relative to age-matched untreated ApoE
-/- mice (Untreated; left panel). 
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heart tissue of ranolazine-treated aortic-constricted B6 and 
aged ApoE
-/- mice (Fig. 6F). Those data show that anti-
ischemic treatment normalized the cardiac lipid overload and 
reduced cardiomyocyte apoptosis in experimental heart fail-
ure models. 
Anti-ischemic Treatment with Ranolazine Improved the 
Cardiac Function of Mice with Signs of Heart Failure 
Ranolazine also reduced the up-regulated heart failure 
marker resistin indicating a positive treatment effect on heart 
function (cf. Fig. 6A, B). In agreement with that notion, 
echocardiography revealed a significant improvement of the 
impaired cardiac function of aortic-constricted B6 mice by 
ranolazine treatment (Fig. 6G). The ejection fraction of un-
treated B6 mice after 6 months of AAC was 28.0 ± 2.6 
whereas the ejection fraction of ranolazine-treated mice was 
44.8 ± 6.4 % (Fig. 6G). 
Ranolazine also improved the cardiac function of aged 
ApoE
-/- mice with severe atherosclerosis. The ejection frac-
tion was 29.5 ± 4.2 % of untreated ApoE
-/- mice, and 45.0 ± 
5.7 % of ranolazine-treated ApoE
-/- mice (Fig. 6H). As a 
control, two months of ranolazine treatment did not affect 
the development of atherosclerotic plaques in the aorta of 18 
month-old ApoE
-/- mice (Fig. 6I). Altogether the data show, 
that anti-ischemic treatment normalized the cardiac lipid 
metabolism at the onset of heart failure and improved the 
cardiac function in two different experimental models of 
heart failure. 
Inhibition of Cellular Respiration by Mild Thiol-Blocking 
with Cystamine Up-Regulated the Cardiac Lipid Metabo-
lism and Induced Heart Failure in ApoE
-/- Mice 
The above findings suggest a causal relationship between 
insufficient oxygen and ATP supply in failing hearts [2, 3] 
and up-regulation of the cardiac lipid metabolism. To further 
analyze the impact of insufficient ATP supply on cardiac 
lipid metabolism gene expression, we inhibited cellular res-
piration in vivo by disulfide poisoning with the mild thiol-
blocking agent cystamine [30, 31]. We chose 4 month-old 
ApoE
-/- mice, which were highly vulnerable to increased 
oxygen and ATP demands due to pressure-overload (cf. Fig. 
2). After four weeks of cystamine treatment (300 mg/kg/d in 
drinking water, ref. [32]), hearts were isolated and analyzed. 
Mild inhibition of cellular respiration by cystamine led to a 
significant reduction of cardiac ATP content by 36.5 ± 10.5 
% relative to untreated ApoE
-/- control mice (n=4, *, p<0.02; 
Fig. 7A). 
Next we asked whether chronic impairment of cellular 
respiration and ATP depletion also affected the cardiac lipid 
metabolism. Microarray gene expression analysis of heart 
tissue demonstrated a significantly increased expression of 
cardiac lipid metabolism genes in cystamine-treated ApoE
-/- 
mice compared to untreated controls as evidenced by the up-
regulation of Fasn, Scd1 and Ucp1 (Fig. 7B). Concomitantly, 
the cardiac lipid content was significantly increased (data not 
shown). The microarray data were confirmed by immunohis-
tology analysis showing increased Fasn, Scd1 and Ucp1 pro-
tein levels on heart sections of cystamine-treated ApoE
-/- 
mice compared to untreated ApoE
-/- and B6 mice (Fig. 7C).  
Similar to aortic-constricted mice (cf. Figs. 4, 6), the   
microarray data also showed a strong up-regulation of the 
cardiac resistin expression in hearts of cystamine-treated 
ApoE
-/- mice (Fig. 7B). The increased expression of the heart 
failure marker resistin correlated with a strongly reduced 
cardiac ejection fraction of 29.0 ± 2.2 % confirming the   
development of heart failure upon cystamine treatment   
(Fig.  7D). In agreement with heart failure, the histology 
analysis of hematoxylin-eosin stained heart sections revealed 
cardiac hypertrophy with dilation after cystamine-treatment 
(Fig.  7E). Altogether the data show that partial inhibition   
of cellular respiration and subsequent ATP depletion up-
regulated the cardiac lipid metabolism and induced signs of 
heart failure in 5 month-old ApoE
-/- mice. 
Myocardial Lipid Accumulation and Key Fat Synthesiz-
ing Enzymes in Cardiac Biopsy Specimens of Patients 
with Heart Failure 
We next analyzed whether up-regulation of the cardiac 
fat metabolism was also a characteristic feature of human 
heart failure. Biopsy specimens of heart muscle were ob-
tained from heart failure patients and from control patients 
without symptoms of heart failure during surgery for mitral 
valve replacement (Fig. 8). Cardiac tissue from failing hearts 
was characterized by a high accumulation of lipids as de-
tected by oil red O staining (Fig. 8A, left panels). For com-
parison, cardiac biopsy specimens from patients without 
heart failure symptoms did not show significant oil red O 
staining (Fig. 8A, right panels).  
Immunohistological analysis detected high protein levels 
of key fat synthesizing enzymes, FASN and SCD1, in the 
hypertrophic myocardial tissue of patients with heart failure 
(Fig. 8B, left, upper and middle panels). In contrast, control 
specimens from patients without heart failure did not show 
significant levels of FASN and SCD1 (Fig. 8B, right, upper 
and middle panels). Heart muscle specimens from patients 
with heart failure also showed significant levels of UCP1 
protein relative to control specimens from patients without 
heart failure (Fig. 8B, lower panels). 
Immunoblot detection was used to quantify protein levels 
of FASN, SCD1 and UCP1 in cardiac tissue specimens from 
patients with heart failure. Quantitative immunoblotting con-
firmed the immunohistology data showing significantly in-
creased protein levels of key lipid synthesizing and oxidizing 
enzymes FASN, SCD1 and UCP1 in cardiac tissue speci-
mens from patients with symptoms of heart failure compared 
to cardiac biopsy specimens from control patients without 
heart failure (Fig. 8C). Thus, lipid overload and up-
regulation of the cardiac lipid metabolism were also present 
in heart specimens of patients with heart failure. 
DISCUSSION 
Identification of a Cardiac Lipid Metabolism Gene   
Cluster in Failing Hearts 
Lipid overload in ischemic and failing heart muscle is es-
tablished since decades [25, 33]. While the accumulation of 
fatty acids in ischemic and failing heart muscle is well 
known, underlying pathomechanisms are incompletely 202    Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011, Vol. 9, No. 3  AbdAlla et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Inhibition of cellular respiration and ATP generation by mild thiol-blocking with cystamine up-regulated the cardiac lipid metabolism 
and induced heart failure in ApoE
-/- mice. A. Cardiac ATP content was determined by luminescence assay of heart tissue extracts from cystamine-
treated (Cystamine; 4 weeks of treatment) ApoE
-/- mice (ApoE
-/-; age 5 months) relative to age-matched untreated ApoE
-/- mice (Untreated) and 
B6 control mice (B6). Data represent mean ± S.D., n=4 mice/group (*, p<0.02, cystamine-treated vs. untreated). B. Effect of cystamine treatment 
(4 weeks) on the expression of lipid metabolism genes was assessed by microarray analysis with heart tissue of 5 month-old, cystamine-treated 
ApoE
-/- mice (Cystamine) relative to untreated age-matched ApoE
-/- mice (Untreated). Gene expression is presented as fold change relative to 
age-matched B6 mice (-fold of B6; *p<0.01). C. Immunohistological detection of Fasn (upper panels), Scd1 (middle panels) and Ucp1 (lower 
panels) was performed with the respective antibodies on heart sections of cystamine-treated (left panels; Cystamine) and untreated (middle pan-
els; Untreated) 5 month-old ApoE
-/- mice (ApoE
-/-). Heart sections of age-matched, untreated B6 mice (B6) are shown for comparison. Histology 
data are representative of at least 3 different mice/group (bar: 40 μm). D. The ejection fraction (expressed in %) of cystamine-treated (Cystamine) 
and untreated (Untreated) 5 month-old ApoE
-/- mice (ApoE
-/-) was determined by echocardiography. Untreated 5 month-old B6 mice (B6) served 
as controls. Data represent mean ± S.D., n=4 mice/group (**, p<0.001, cystamine-treated vs. untreated). E. Hematoxylin-eosin (HE)- stained 
heart sections of a 5 month-old cystamine-treated ApoE
-/- mouse (left panel; Cystamine) and an age-matched untreated ApoE
-/- mouse (right 
panel; Untreated). Histology data are representative of at least 3 different mice/group (bar: 2 mm). 
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Fig. (8). Myocardial lipid accumulation and lipid metabolizing enzymes in cardiac biopsy specimens of patients with heart failure. A. Oil red 
O (Oil red) staining of frozen heart sections showed cardiac lipid load in myocardial biopsy specimens isolated from patients with heart fail-
ure (Heart failure patients, n=2; left panels) compared to control patients (Controls, n=2; right panels), bar: 40 μm. B. Upper panels: immuno-
histological detection of FASN with F(ab)2 fragments of FASN-specific antibodies was performed in myocardial biopsy specimens of two 
patients with heart failure (left panels; Heart failure patients) relative to heart muscle specimens of two control patients (right panels; Con-
trols). Middle panels: immunohistochemistry localized the key fatty acid synthesizing enzyme SCD1 in myocardial biopsy specimens of two 
patients with heart failure (left panels) whereas SCD1 was barely detectable with SCD1-specific antibodies in heart muscle biopsy specimens 
of two control patients (right panels). Lower panels show detection of high UCP1 protein levels in myocardial biopsy specimens of failing 
hearts (left panels; n=2) while UCP1 was almost undetectable in heart biopsies of control patients (right panels; n=2). Cell nuclei were stained 
with hematoxylin (bar: 40 μm). C. Left panels: Immunoblot detection of FASN, SCD1 and UCP1 in heart biopsy specimens of five patients 
with heart failure (Heart fail.) relative to four control patients (Cont.). As loading control, GAPDH was used. Right panels show quantifica-
tions of relative protein levels (expressed as percentage of control; %) of FASN, SCD1 and UCP1 in myocardial biopsy specimens of patients 
with heart failure (Heart failure; n=5) relative to control patients (Control; n=4) as determined by densitometric immunoblot blot scanning  
(± S.E.M.; *, p<0.05). 
understood. The heart mainly relies on the uptake of fatty 
acids from the blood for energy generation, whereas the role 
of de novo synthesis of fatty acids by cardiac cells is negligi-
ble under normal conditions [25, 34]. In contrast to normoxic 
conditions, several studies have found that the capacity of 
cardiac cells of synthesizing fatty acids was increased under 
hypoxic conditions [35, 36]. However, data on the cardiac fat 
metabolism at the onset of heart failure (characterized by 
insufficient oxygen supply) are lacking. In view of the im-
portance of lipids for cardiac energy generation and the re-
duced myocardial energy efficiency in heart failure, we ana-
lyzed the expression of fat metabolism genes at the onset of 
heart failure. Microarray gene expression and immunohis-
tological analyses detected the strong up-regulation of a clus-
ter of genes involved in fat synthesis, storage and oxidation 
in the failing myocardium of three different models of pres-

A:!
.
%
! :6!
(
 !:
!: %
! :6!
(


9#/
#7$
=0$
9#/
#7$
=0$
-07%
%
! :* * 

$
 
$



9#/ #7$



$

=0$

'


:
*

(
!







:


;


:


"

!:
%
!
 :6!

!:
%
!
 :6!

!:
%
!
 :6!

204    Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011, Vol. 9, No. 3  AbdAlla et al. 
sure overload- and severe atherosclerosis-induced heart   
failure. Moreover, up-regulation of key fat metabolizing   
enzymes was also present in cardiac biopsy specimens of 
patients with heart failure. 
Lipids Enhance Cardiomyocyte Death In Vitro and   
In Vivo 
The up-regulation of the lipid metabolism in the failing 
heart correlated with an increased accumulation of cardiac 
lipids in different animal models and patients. Accumulation 
of lipids is detrimental to the myocardium as evidenced with 
isolated cardiomyocytes or genetic models of lipotoxic car-
diomyopathy [27, 37-39]. Several possible mechanisms of 
injury could account for the deleterious effects of free fatty 
acids to the myocardium: (i) accumulation of toxic interme-
diates of FFA metabolism, (ii) inhibition of glucose utiliza-
tion, and (iii) uncoupling of oxidative metabolism [40]. Our 
data are complementary to those studies showing that over-
expression of the key palmitate synthesizing enzyme, Fasn, 
increased markers of cardiomyocyte death similarly as did 
palmitate. In agreement with lipotoxicity, up-regulation of 
the cardiac fat metabolism in vivo in different models of 
heart failure correlated with an enhanced rate of cardiomyo-
cyte death during the transition from cardiac hypertrophy to 
overt cardiac failure. 
Catecholamines and Angiotensin II are Related to   
Cardiac Lipid Overload 
Which factors trigger the cardiac fat metabolism during 
the development of heart failure? Heart failure is character-
ized by a maladaptive neurohormonal activation and 
catecholamine accumulation. It is well established that 
catecholamines exert major metabolic effects, which could 
finally culminate in enhanced lipogenesis and lipid overload: 
Catecholamines induce inappropriate FFA use by triggering 
(i) an increase in serum levels of FFAs, (ii) wasteful cycling 
of FFAs through enhanced intramyocardial lipolysis, and 
(iii) FFA-mediated suppression of glucose metabolism [41]. 
Concomitantly, catecholamines increase the RNA stability of 
FASN [42], and trigger UCP1 gene expression via -
adrenergic receptor-mediated stimulation of cAMP [43]. 
Apart from over-activation of the adrenergic system, the 
angiotensin II AT1 receptor, another key player in the devel-
opment of heart failure, also up-regulates the cardiac fat me-
tabolism by increasing the expression of FASN [44, 45]. The 
increased cardiac lipids could further stimulate the cardiac 
lipid metabolism by activation of transcriptional activators 
such as CCAAT/enhancer-binding protein (C/EBP) alpha 
(this microarray study, GSE25765-8, and ref. 44), and 
C/EBP alpha-dependent fat metabolism genes [46, 47]. Thus, 
neurohormonal activation during the pathogenesis of heart 
failure could be causally involved in enhancing the expres-
sion of fat metabolism genes and triggering lipid-induced 
lipid overload. 
Anti-Ischemic Treatment with Ranolazine Prevents Up-
Regulation of the Cardiac Fat Metabolism and Improves 
Heart Failure Signs 
As a direct or indirect consequence of neurohormonal ac-
tivation, the failing heart suffers from increased oxygen and 
ATP consumption [3]. However, due to uncoupled and 
wasteful energy generation, oxygen supply is not sufficient 
to meet the increased ATP demand. In fact, cardiac ATP 
levels are decreased during the pathogenesis of heart failure 
[3]. Our data are complementary to those findings and indi-
cate a causal relationship between insufficient oxygen and 
ATP supply, up-regulation of fat metabolism genes and heart 
failure because anti-ischemic treatment with ranolazine   
prevented the up-regulation of fat metabolism genes and 
improved heart failure signs in two different models of heart 
failure. Notably, ranolazine exerted its anti-ischemic effects 
without lowering blood pressure [29] or reducing atheroscle-
rotic plaques.  
Insufficient Oxygen and ATP Supply Trigger the   
Cardiac Fat Metabolism 
A causal role of oxygen deprivation in the up-regulation 
of the cardiac fat metabolism is suggested by a previous 
finding, which shows that hypoxia could trigger the expres-
sion of key fatty acid synthesizing enzymes such as Scd1 
[48]. Inhibition of cellular respiration and ATP generation by 
the mild thiol-blocking agent cystamine further supported 
the impact of oxygen/ATP deprivation for the cardiac lipid 
metabolism. Similarly as did pressure overload (imposed by 
aortic constriction), depletion of myocardial ATP content by 
cystamine not only up-regulated the cardiac lipid metabolism 
but also induced heart failure in ApoE
-/- mice within four 
weeks. Those experiments strongly indicate that ATP deple-
tion, which is a characteristic feature of heart failure in pa-
tients and experimental models [2, 3, 49], is causally in-
volved in triggering dysfunction of the cardiac lipid metabo-
lism and toxic lipid overload. In agreement with that conclu-
sion, heart biopsy specimens of patients with heart failure 
showed massive lipid accumulation and high protein levels 
of key fat metabolizing enzymes FASN, SCD1 and UCP1. 
Altogether, the herein identified cluster of lipid metabo-
lism genes could be directly triggered by chronic ATP deple-
tion, which is a hallmark of heart failure [2, 3]. The resulting 
dysfunction of the essential cardiac lipid metabolism could 
initiate a vicious circle of lipid-induced fat synthesis. The 
rich supply of cardiac lipids cannot be used for ATP genera-
tion because accumulated lipids in concert with sympathetic 
over-stimulation induce the excessive accumulation of UCP, 
which uncouples fat oxidation from ATP generation [7, 43]. 
As a consequence toxic lipid overload develops and triggers 
cardiomyocyte death. Thus, despite of excessive substrate 
supply, cardiac energy depletion may occur, marking the 
transition from adaptive cardiac hypertrophy to heart failure.  
CONCLUSION 
The current study demonstrates that up-regulation of the 
cardiac lipid metabolism and toxic lipid overload mark the 
onset of heart failure in different experimental models of 
heart failure and patients. Triggered by oxygen/ATP deple-
tion, cardiac lipid overload may promote heart failure by 
enhancing cardiomyocyte death. As a result of the study, a 
new treatment option of heart failure is proposed: Increased 
cardiac oxygen delivery by anti-ischemic treatment with 
ranolazine could normalize the cardiac lipid overload and 
improve signs of heart failure, at least in experimental models. Cardiac Lipid Metabolism in Heart Failure  Cardiovascular & Hematological Agents in Medicinal Chemistry, 2011, Vol. 9, No. 3    205 
ABBREVIATIONS 
AAC =  Abdominal  aortic  constriction 
ApoE =  Apolipoprotein  E 
ApoE
-/- =  Apolipoprotein  E-deficient 
B6 mice   =  C57BL/6J mice 
Bdh  =  1, 3-hydroxybutyrate dehydrogenase type 1 
C/EBP alpha  =  CCAAT/enhancer-binding protein alpha 
Fasn =  Fatty  acid  synthase 
FFA =  Free  fatty  acid 
Gapdh =  Glyceraldehyde-3-phosphate dehydrogenase 
HE =  Hematoxylin  and  eosin 
Nppa  =  Natriuretic peptide precursor type A 
Nppb  =  Natriuretic peptide precursor type B 
Retn =  Resistin 
Scd1  =  Stearoyl Coenzyme-A desaturase 1 
Ucp =  Uncoupling  protein 
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